Skip to main content
Top
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology 6/2007

01-06-2007 | Laboratory Investigation

Retinal toxicity of triamcinolone’s vehicle (benzyl alcohol): an electrophysiologic and electron microscopic study

Authors: Tamer A. Macky, Dina Helmy, Nihal El Shazly

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 6/2007

Login to get access

Abstract

Purpose

To assess retinal toxicity of the vehicle of triamcinolone, benzyl alcohol (BA), when injected into the vitreous cavity of rabbits.

Methods

This prospective comparative experimental study included 24 pigmented rabbits assigned into two groups: group 1 (experimental, n = 12) received intravitreal 0.1 ml of BA, and group 2 (control, n = 12) received intravitreal 0.1 ml of balanced salt solution (BSS); all injections were done in the right eyes. Clinical examinations [slit lamp biomicroscopy, indirect ophthalmoloscopy, and three intraocular pressure (IOP) measurements] were done on both eyes before injection, at 1 and 3 h post injection, together with electroretinograms (ERGs) at 3 days, 1, 2, 4, and 6 weeks following injections. Three rabbits from each group were euthanased at 1, 2, 4, or 6 weeks and eyes were sent for light and electron microscopic examination for quantitative morphometric measurements.

Results

The mean amplitudes of the a and b waves of the BA-injected eyes were 6.42 ± 9.02 μv and 11.18 ± 15.18 μv at 3 days, respectively, which were significantly reduced compared with the BSS-injected eyes (30.87 ± 8.22 μv and 57.90 ± 13.38 μv, respectively; P < 0.01 t-test) and the non-injected contralateral eyes (36.20 ± 7.85 μv and 64.10 ± 9.36 μv, respectively; P < 0.01 t-test). These ERG responses continued to be significantly reduced in the BA-injected eyes (P < 0.01 t-test) throughout the study period. The mean ganglion cell count was significantly reduced (P < 0.005 t-test) in the BA-injected eyes (8.42 ± 2.4) compared with the BSS- and non-injected eyes (16.42 ± 3.9 and 16.5 ± 4.2, respectively). The mean thicknesses of the inner nuclear layer (INL) and outer nuclear layer (ONL) were significantly reduced (P < 0.005 t-test) in the BA-injected eyes (3.78 ± 0.96 μm and 11.77 ± 1.29 μm, respectively) compared with the BSS- (6.1 ± 0.92 μm and 21.82 ± 0.95 μm, respectively) and non-injected eyes (7.05 ± 1.9 μm and 22.49 ± 1.01 μm, respectively). Electron microscopy showed moderate to severe intracellular changes in the ganglion cell layer, INL, ONL, and photoreceptor layer at 6 weeks in BA-injected eyes, with no significant changes in BSS-injected eye. There was no significant rise in the IOP or clinical evidence of increased lens density during the study period in any of the eyes.

Conclusions

Triamcinolone acetonide’s vehicle, BA, produced severe ERG and structural damage to the retina when injected intravitreally.
Literature
1.
go back to reference Androudi S, Letko E, Meniconi M, Papadaki T, Ahmed M, Foster CS (2005) Safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema. Ocul Immunol Inflamm 13:205–212PubMedCrossRef Androudi S, Letko E, Meniconi M, Papadaki T, Ahmed M, Foster CS (2005) Safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema. Ocul Immunol Inflamm 13:205–212PubMedCrossRef
2.
go back to reference Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, Ffytche TJ, Marshall J (2001) Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 108:765–772PubMedCrossRef Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, Ffytche TJ, Marshall J (2001) Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 108:765–772PubMedCrossRef
3.
go back to reference Avci R, Kaderli B (2005) Intravitreal triamcinolone injection for chronic diabetic macular edema with severe hard exudates. Graefes Arch Clin Exp Ophthalmol 21:1–8 Avci R, Kaderli B (2005) Intravitreal triamcinolone injection for chronic diabetic macular edema with severe hard exudates. Graefes Arch Clin Exp Ophthalmol 21:1–8
4.
go back to reference Bakri SJ, Shah A, Falk NS, Beer PM (2005) Intravitreal preservative-free triamcinolone acetonide for the treatment of macular edema. Eye 19:686–688PubMedCrossRef Bakri SJ, Shah A, Falk NS, Beer PM (2005) Intravitreal preservative-free triamcinolone acetonide for the treatment of macular edema. Eye 19:686–688PubMedCrossRef
5.
go back to reference Bonanomi MT, Susanna R Jr (2005) Intravitreal triamcinolone acetonide as adjunctive treatment for neovascular glaucoma. Clinics 60:347–350PubMedCrossRef Bonanomi MT, Susanna R Jr (2005) Intravitreal triamcinolone acetonide as adjunctive treatment for neovascular glaucoma. Clinics 60:347–350PubMedCrossRef
6.
go back to reference Boscia F, Furino C, Dammacco R, Ferreri P, Sborgia L, Sborgia C (2005) Intravitreal triamcinolone acetonide in refractory pseudophakic cystoid macular edema: functional and anatomic results. Eur J Ophthalmol 15:89–95PubMed Boscia F, Furino C, Dammacco R, Ferreri P, Sborgia L, Sborgia C (2005) Intravitreal triamcinolone acetonide in refractory pseudophakic cystoid macular edema: functional and anatomic results. Eur J Ophthalmol 15:89–95PubMed
7.
go back to reference Danis RP, Ciulla TA, Pratt LM, Anliker W (2000) Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 20:244–250PubMedCrossRef Danis RP, Ciulla TA, Pratt LM, Anliker W (2000) Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 20:244–250PubMedCrossRef
8.
go back to reference Drury RA, Walllington EB (1980) Carlton’s histological techniques, 5th edn. Oxford University Press, London Drury RA, Walllington EB (1980) Carlton’s histological techniques, 5th edn. Oxford University Press, London
9.
go back to reference Garcia-Arumi J, Boixadera A, Giralt J, Martinex-Castillo V, Gomez-Ulla F, Corcostegui B, Garcia-Arumi E (2005) Comparison of different techniques for purification of triamcinolone acetonide suspension for intravitreal use. Br J Ophthalmol 89:1112–1114PubMedCrossRef Garcia-Arumi J, Boixadera A, Giralt J, Martinex-Castillo V, Gomez-Ulla F, Corcostegui B, Garcia-Arumi E (2005) Comparison of different techniques for purification of triamcinolone acetonide suspension for intravitreal use. Br J Ophthalmol 89:1112–1114PubMedCrossRef
10.
go back to reference Gibran SK, Cullinane A, Jungkim S, Cleary PE (2006) Intravitreal triamcinolone for diffuse diabetic macular edema. Eye 20:720–724PubMedCrossRef Gibran SK, Cullinane A, Jungkim S, Cleary PE (2006) Intravitreal triamcinolone for diffuse diabetic macular edema. Eye 20:720–724PubMedCrossRef
11.
go back to reference Glauert AM (1965) The fixation and embedding of biological specimens. In: Key DH (ed) Techniques for electron microscopy, 1st edn. Davis, Philadelphia Glauert AM (1965) The fixation and embedding of biological specimens. In: Key DH (ed) Techniques for electron microscopy, 1st edn. Davis, Philadelphia
12.
go back to reference Hayat MA (1989) Basic techniques for transmission electron microscopy, 1st edn. Academic Press, N.Y. Hayat MA (1989) Basic techniques for transmission electron microscopy, 1st edn. Academic Press, N.Y.
13.
go back to reference Hernaez-Ortega MC, Soto-Pedre E (2004) A simple and rapid method for purification of triamcinolone acetonide suspension for intravitreal injection. Ophthalmic Surg Lasers Imaging 135:350–351 Hernaez-Ortega MC, Soto-Pedre E (2004) A simple and rapid method for purification of triamcinolone acetonide suspension for intravitreal injection. Ophthalmic Surg Lasers Imaging 135:350–351
14.
go back to reference Hida T, Chandler D, Arena JE, Machemer R (1986) Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol 101:190–195PubMed Hida T, Chandler D, Arena JE, Machemer R (1986) Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol 101:190–195PubMed
15.
go back to reference Jonas JB, Hayler JK, Panda-Jonas S (2000) Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol 84:1064–1067PubMedCrossRef Jonas JB, Hayler JK, Panda-Jonas S (2000) Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol 84:1064–1067PubMedCrossRef
16.
go back to reference Jonas JB, Hayler JK, Sofker A, Panda-Jonas S (2001) Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 131:468–471PubMedCrossRef Jonas JB, Hayler JK, Sofker A, Panda-Jonas S (2001) Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 131:468–471PubMedCrossRef
17.
go back to reference Jonas JB, Hayler JK, Söfker A, Panda-Jonas S (2001) Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone. J Glaucoma 10:284–287PubMedCrossRef Jonas JB, Hayler JK, Söfker A, Panda-Jonas S (2001) Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone. J Glaucoma 10:284–287PubMedCrossRef
18.
go back to reference Jonas JB, Hayler JK, Panda-Jonas S (2001) Intravitreal injection of crystalline cortisone as treatment of pre-phthisical ocular hypotony. Graef Arch Clin Exp Ophthalmol 239:464–465 Jonas JB, Hayler JK, Panda-Jonas S (2001) Intravitreal injection of crystalline cortisone as treatment of pre-phthisical ocular hypotony. Graef Arch Clin Exp Ophthalmol 239:464–465
19.
go back to reference Jonas JB, Kreissig I, Hugger P, Sauder G, Panda-Jonas S, Degenring R (2003) Intravitreal triamcinolone for exudative age related macular degeneration. Br J Ophthalmol 87:462–468PubMedCrossRef Jonas JB, Kreissig I, Hugger P, Sauder G, Panda-Jonas S, Degenring R (2003) Intravitreal triamcinolone for exudative age related macular degeneration. Br J Ophthalmol 87:462–468PubMedCrossRef
20.
go back to reference Jonas JB, Akkoyun I, Budde WM, Kreissig I, Degenring RF (2004) Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol 122:218–222PubMedCrossRef Jonas JB, Akkoyun I, Budde WM, Kreissig I, Degenring RF (2004) Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol 122:218–222PubMedCrossRef
21.
go back to reference Lee H, Shah GK (2005) Intravitreal triamcinolone as primary treatment of cystoid macular edema secondary to branch retinal vein occlusion. Retina 25:551–555PubMedCrossRef Lee H, Shah GK (2005) Intravitreal triamcinolone as primary treatment of cystoid macular edema secondary to branch retinal vein occlusion. Retina 25:551–555PubMedCrossRef
22.
go back to reference Marmor ME (1979) Retinal detachment from hyperosmotic intravitreal injections. Invest Ophthalmol Vis Sci 18:1237–1244PubMed Marmor ME (1979) Retinal detachment from hyperosmotic intravitreal injections. Invest Ophthalmol Vis Sci 18:1237–1244PubMed
23.
go back to reference Martinez JA (2003) Intravitreal triamcinolone acetonide for bilateral acquired parafoveal telangiectasis. Arch Ophthalmol 121:1658–1659PubMedCrossRef Martinez JA (2003) Intravitreal triamcinolone acetonide for bilateral acquired parafoveal telangiectasis. Arch Ophthalmol 121:1658–1659PubMedCrossRef
24.
go back to reference McCuen BW 2nd, Bessler M, Tano Y, Chandler D, Machemer R (1981) The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol 91:785–788PubMed McCuen BW 2nd, Bessler M, Tano Y, Chandler D, Machemer R (1981) The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol 91:785–788PubMed
25.
go back to reference Ranson NT, Danis RP, Ciulla TA, Pratt L (2002) Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularization after laser treatment in macular degeneration. Br J Ophthalmol 86:527–529PubMedCrossRef Ranson NT, Danis RP, Ciulla TA, Pratt L (2002) Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularization after laser treatment in macular degeneration. Br J Ophthalmol 86:527–529PubMedCrossRef
26.
go back to reference Spaide RF, Sorenson J, Maranan L (2005) Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 112:301–304PubMedCrossRef Spaide RF, Sorenson J, Maranan L (2005) Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 112:301–304PubMedCrossRef
27.
go back to reference Sutter FK, Gillies MC (2003) Intravitreal triamcinolone for radiation-induced macular edema. Arch Ophthalmol 121:1491–1493PubMedCrossRef Sutter FK, Gillies MC (2003) Intravitreal triamcinolone for radiation-induced macular edema. Arch Ophthalmol 121:1491–1493PubMedCrossRef
28.
go back to reference Williamson TH, O’Donnell A (2005) Intravitreal triamcinolone acetonide for cystoid macular edema in non-ischemic central retinal vein occlusion. Am J Ophthalmol 139:860–866PubMedCrossRef Williamson TH, O’Donnell A (2005) Intravitreal triamcinolone acetonide for cystoid macular edema in non-ischemic central retinal vein occlusion. Am J Ophthalmol 139:860–866PubMedCrossRef
29.
go back to reference Yang CS, Khawly JA, Hainsworth DP, Chen SN, Ashton P, Guo H, Jaffe GJ (1998) An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch Ophthalmol 116:69–77PubMed Yang CS, Khawly JA, Hainsworth DP, Chen SN, Ashton P, Guo H, Jaffe GJ (1998) An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch Ophthalmol 116:69–77PubMed
30.
go back to reference Young S, Larkin G, Branley M, Lightman S (2001) Safety and efficacy of intravitreal triamcinolone for cystoid macular edema in uveitis. Clin Exp Ophthalmol 29:2–6CrossRef Young S, Larkin G, Branley M, Lightman S (2001) Safety and efficacy of intravitreal triamcinolone for cystoid macular edema in uveitis. Clin Exp Ophthalmol 29:2–6CrossRef
31.
go back to reference Xuan B, Wang T, Chiou GCY, Dalinger IL, Shkineva TK, Shevelev SA (2002) Effects of C-nitropyrazoles and C-nitroazoles on ocular blood flow and retinal function recovery after ischemic insult. Acta Pharmacol Sin 23:705–712PubMed Xuan B, Wang T, Chiou GCY, Dalinger IL, Shkineva TK, Shevelev SA (2002) Effects of C-nitropyrazoles and C-nitroazoles on ocular blood flow and retinal function recovery after ischemic insult. Acta Pharmacol Sin 23:705–712PubMed
Metadata
Title
Retinal toxicity of triamcinolone’s vehicle (benzyl alcohol): an electrophysiologic and electron microscopic study
Authors
Tamer A. Macky
Dina Helmy
Nihal El Shazly
Publication date
01-06-2007
Publisher
Springer-Verlag
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 6/2007
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-006-0459-3

Other articles of this Issue 6/2007

Graefe's Archive for Clinical and Experimental Ophthalmology 6/2007 Go to the issue

Announcements

Announcements